Importing Medical Devices for Non-Clinical Testing in the United States

Medical devices often enter the United States long before commercial launch or a human clinical investigation. They may be needed for biocompatibility testing, sterilization validation, bench and performance testing, preclinical animal studies, cadaver laboratories, packaging and transport validation, engineering verification, or failure analysis. These shipments are non-clinical, but they still require deliberate customs and FDA planning.

The Entry Must Tell One Consistent Story

A non-clinical purpose does not make the article invisible to FDA. The entry should clearly identify that the device is being imported for non-clinical testing rather than for commercial distribution or use in a human clinical investigation. The broker instructions, commercial invoice, FDA product information, quantities, receiving laboratory, and stated purpose should therefore tell one consistent story.

Descriptions such as “samples,” “research materials,” or “no commercial value” are usually inadequate by themselves.

The Testing Pathway Affects Documentation

The testing pathway also affects labeling and supporting documentation. Devices intended solely for laboratory-animal research should be clearly identified and labeled for investigational animal use.

A cadaver laboratory is generally non-clinical because it does not involve living human subjects, but the documentation should still identify the facility and protocol and confirm that the devices will not be used on living people. If imported tissue, organisms, biological indicators, or other biological materials accompany the devices, separate public-health or agricultural controls may also need assessment.

Define the Device’s Final Disposition

The import plan should establish the device’s development status, the specific testing activity, whether units are sterile or previously used, who owns them, where they will be delivered, and what will happen after testing.

This matters because some units may be consumed, sectioned, contaminated, implanted in animals, deliberately damaged, retained as evidence, returned overseas, or destroyed. Packaging-validation samples and failure-analysis returns may also require very different descriptions from unused engineering prototypes.

Customs Treatment Must Match the Outcome

Customs treatment should match that final disposition. A regular import entry is often appropriate where the devices will be consumed or destroyed during testing.

A temporary importation arrangement may be available for articles brought into the United States solely for testing, experimental, or review purposes and not for sale, but it creates bond, export-or-destruction, and deadline controls. It should not be selected merely because the shipment is temporary or has no sale price. Even where no sale occurs, a defensible customs value must still be established.

MDD Options can structure the import before shipment, serve as Importer of Record where appropriate, coordinate FDA entry data and broker instructions, receive and store devices, distribute them to U.S. laboratories, and document returns or destruction. The same infrastructure can then support the transition into a human clinical investigation or MDD Options’ hybrid commercial-distribution model, while consulting support remains available for unusual testing pathways or agency questions.